TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of compliance with dietary advice
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Temporal Experience of Pleasure Scale (TEPS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inventory of Depressive Symptomatology (IDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of the abortion rate
Endpoint domain: Mortality/survival
Primary endpoint: Pain Score (Visual analog Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical failure (fever)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical failure (death)
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge of own vaccination status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin collagen and elastin quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Symptoms of central sensitisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sTNFRII levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Emotional distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life objective and subjective
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oscillatory delta power in the sleep electroencephalogram (EEG) during non rapid eye movement (REM) sleep stages N2 and N3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG measures of sleep quality: sleep duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom burden assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Constipation Risk Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratinised tissue width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interproximal Clinical attachment level (iCAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lower extremity muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total pathological complete response rate (tpCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrical activity of deltoid, biceps, triceps, wrist flexor, wrist extensor muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of opevesostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sacroiliac joint pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability (Enrollment)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability (Satisfaction)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of adverse events of severity grade 2 or more
Endpoint domain: Adverse events/effects
Primary endpoint: Positive predictive value of the blood ctDNA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of the blood ctDNA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the blood ctDNA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the blood ctDNA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetration-aspiration Scale (PAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement or resolution of the syrinx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Occurrence of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: New malignancies and hematologic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of achieving transfusion independence for at least 12 consecutive months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Achieving SALT Score ≤20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: three-year cumulative incidence of myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Seattle angina pectoris scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Non-recurrence of sinus cavity oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, Electrocardiograms (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of intravitreal injection of autologous CD34+ cells
Endpoint domain: Adverse events/effects
Primary endpoint: Weaning success prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Montreal Cognitive Assessment (MoCA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Wechsler Memory Scale III Logical Memory I & II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall detection rate of gastrointestinal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Skin Picking Scale Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage volume change of recurrent haematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Number of Sensitive Teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Receiving PCV-13 Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Level of state-trait anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Systolic Blood Pressure Response to Momentary Psychosocial Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Task Strain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Social Conflict
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total morphine consumption over 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of single dose vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of single dose vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of improvement in motor aspects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface qualifier image change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total absorption over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge retention about epidural analgesia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Risk retention about epidural analgesia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average change in reported pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coma Recovery Scale - revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Technical success of localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment Emergent Serious Adverse Events (SAEs) and Unexpected Adverse Events (UAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline scar Global Aesthetic Improvement Scale at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voxel-based morphometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response to electrical stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health care worker motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health care worker performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Health care worker satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Splanchnic regional oxygenation (rSO2S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of pain intensity difference (SPID) over 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Satisfaction with the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Dropped Out of Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Scale-Level Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Volume of the nasal and maxillary sinus airway complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-vaccination Strain-specific HAI Antibody Geometric Mean Fold Rises (GMFRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-vaccination Strain-specific MN Antibody Geometric Mean Fold Rises (GMFRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in HAI Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Irreversible gingival recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in Fiberoptic Endoscopic Examination of Swallowing (FEES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in The Fiberoptic Endoscopic Dysphagia Severity Scale (FEDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of baseline Standardized Swallowing Assessment (SSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety, depression, and stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fetal pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ratio of personalised care projects completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of diarrhea (grade ≥2)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with abnormal hematology and chemistry laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of participants with grading shifts in hematology and chemistry laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: onset times of motor and sensory blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-related adverse events (AEs) and serious adverse events (SAEs) at Grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in nerve conduction and velocity in motor nerve conduction studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in nerve conduction and velocity in sensory nerve conduction studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional cure of chronic hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Decisional conflicts for COVID-19 testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive rate of bacterial biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with a negative pharyngeal NAAT for Neisseria gonorrhoeae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Western Ontario And MacMaster Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Subjects Receiving Targeted Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Peak Maximum Effect (Emax) for Drug Liking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Take Drug again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Roland-Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The Perceived Global Impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: % of patients achieving the collection of ≥2×10^6 CD34+ cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of participants' PLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: recurrent rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in subjective gastro-oesophageal reflux (GOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Objective gastro-oesophageal reflux (GOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Child material and social deprivation (MSD)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Asymptomatic SARS-CoV-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quantitative description
Endpoint domain: General outcomes
Primary endpoint: Quality of physical health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of mental health symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Patient urine output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence and incidence of functional disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence and incidence of mild cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence and incidence of dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Conversion rate of normal to mild cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Conversion rate of mild cognitive impairment to dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence and incidence of movement disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effectiveness of non invasive hemodynamic monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients achieving VGPR or CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in number of points on the Child-Pugh scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-emergence LUS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference in Prescription Monitoring Program verified opioid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference in Pain, Enjoyment, General Activity (PEG) Scale Summed Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of mothers changing health care providers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative wound complication
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Response Score on CG-CAHPS Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients with adequately controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating vitamin D photoisomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in interpalpebral fissure during opening and spontaneous blinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose of levothyroxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change of parameter of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cotinine-confirmed quit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in mental health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in irrationality
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: median of disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Delivery within 12 hours
Endpoint domain: Mortality/survival
Primary endpoint: Cyst diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgG Anti-S response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in immune and inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in immune cell profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in self-reported ratings of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUCinf of ABP 501-HCF and ABP 501-LCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ABP 501-HCF and ABP 501-LCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days until symptom-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported knee function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patellofemoral pain recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction of therapists
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Age-appropriate hand assessment (HAI/mini-AHA/AHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal tolerable dose of Topotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain post procedure
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Differentiation between epileptic seizure and psychogenic non-epileptic seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prognosis prediction of patients with epileptic seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with new-onset venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Investigators Global Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Profile Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle severity in hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle severity in the face and neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSDI12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response Rate to Neratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speech recognition accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute numbers of stage III and IV cancers diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes